Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study

Annals of Clinical and Laboratory Science

Volumn 30, Issue 3, 2000, Pages 259-265

  Masood, S ^a   Bui, M M ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

Breast cancer; HER 2 neu; HercepTest; Immunohistochemistry; Overexpression

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; BREAST EPITHELIUM; CANCER IMMUNOTHERAPY; COST EFFECTIVENESS ANALYSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 0033868761     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumor antigen
2. The product of the human c-erb B-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
3. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
5. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
6. C-erb B-2 Onco-protein expression in primary and advanced breast cancer
7. Prognostic importance of c-erb B2 expression in breast cancer
8. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
9. The prognostic value of c-erb B2 in primary breast carcinomas: A study on 942 cases
10. C-erb B2 Expression and response to adjuvant therapy in women with node-positive early breast cancer
11. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
12. Phase II study of weekly intravenous recombinant humanized anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpression metastatic breast cancer
13. Efficacy and safety of Herceptin (humanized anti-HER-2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
14. Addition of Herceptin (humanized anti-HER-2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled Phase III trial
15. Clinical highlights from the National Cancer Data Base, 1999
16. Prognostic factors in breast cancer: Use of cytologic preparations
17. Proto-oncogene abnormalities in human breast cancer: Correlations with anatomic features and clinical course of disease
18. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential sources of error in immunohistochemical studies of oncogene expression
19. Analysis of c-erb B2 expression using a panel of commercially available antibodies
20. ERB B-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogenerity in human breast cancer
21. Optimization of immunohistochemical detection of erbB2 in human breast cancer: Impact of fixation
22. Marked intratumoral heterogeneity of the protooncogene HER- 2/neu determined by three different detection systems
23. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system